Clinical Trials Browser

Phase 1 × INDUSTRY × Sirolimus × Clear all

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06528301 2026-01-12

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Phase 1 Recruiting

106 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

190 enrolled

Breast

Breast Neoplasms

NCT06743503 2025-09-18

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

Phase 1 Recruiting

70 enrolled

Recurrence

NCT06941142 2025-04-23

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase 1 Not yet recruiting

382 enrolled

Breast

Advanced Breast Cancer

NCT05508620 2022-08-23

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Phase 1 Unknown

270 enrolled

Other solid neoplasm

Malignant Solid Tumors

NCT05125523 2022-01-25

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

Phase 1 Unknown

264 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01390818 2017-03-07

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

146 enrolled 42 charts

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT00993499 2015-10-07

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Phase 1 Completed

44 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00890500 2013-10-08

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Phase 1 Completed

12 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

Clinical Trials

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.